Drug details

Copiktra (duvelisi capsules)

type of Antineoplastics PI3K Inhibitors

Copiktra (duvelisib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies, and for the treatment of relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

This drug may have the following side effects:

• nausea,
• rash,
• fever,
• fatigue,
• cough,
• pneumonia,
• anemia
• low white blood cell count (neutropenia),
• diarrhea or colitis,
• upper respiratory infection,
• musculoskeletal pain, and

The following drugs are related to Copiktra, either as a replacement or used together:

• Belrapzo (bendamustine hydrochloride injection)
• Vivimusta (bendamustine hydrochloride injection)
• Vegzelma (bevacizumab-adcd injection)
• Leustatin (cladribine injection for intravenous infusion only)
• Cytoxan (cyclophosphamide)
• Cytarabine (cytarabine)
• Sprycel (dasatinib)
• Doxorubicin Hydrochloride Injection (doxorubicin hydrochloride injection)
• Fludara (fludarabine)
• Fludarabine Phosphate Injection (fludarabine phosphate injection)
• Hydrea (hydroxyurea)
• Zynlonta (loncastuximab tesirine-lpyl for injection)
• Lunsumio (mosunetuzumab-axgb injection)
• Riabni (rituximab-arrx injection)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)
• Tabloid (thioguanine)